APA (7th ed.) Citation

Ruzicka, M. (2023). Therapeutic RIG-I activation enhances survival and induces sensitivity to immune checkpoint blockade therapy in preclinical models of AML. https://doi.org/10.5282/edoc.31751

Chicago Style (17th ed.) Citation

Ruzicka, Michael. Therapeutic RIG-I Activation Enhances Survival and Induces Sensitivity to Immune Checkpoint Blockade Therapy in Preclinical Models of AML. München, 2023. https://doi.org/10.5282/edoc.31751.

MLA (9th ed.) Citation

Ruzicka, Michael. Therapeutic RIG-I Activation Enhances Survival and Induces Sensitivity to Immune Checkpoint Blockade Therapy in Preclinical Models of AML. 2023. https://doi.org/10.5282/edoc.31751.